Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02893293 · ClinicalTrials.gov registry record · Phase 4

Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI

A Phase 4 study of Osteonecrosis, sponsored by Stanford University.

Completed
Registry status
Phase 4
Development phase
14
Enrollment target
1
Study location

NCT02893293 is a Phase 4 study of Osteonecrosis that has completed, run by Stanford University. The registered enrollment target is 14 participants, below the 2,921-participant average among 7 other Osteonecrosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02893293, a Phase 4 study of Osteonecrosis, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 4
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

The goal of the project is to evaluate osteonecrosis before and after decompression surgery with ferumoxytol-enhanced MRI.

Conditions Studied

Interventions

  • DRUG Ferumoxytol-enhanced magnetic resonance imaging
  • DEVICE Magentic Resonance Imaging

Study Locations (1)

California

  • Lucile Packard Children's Hospital - Stanford

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2015-05
Est. Completion 2023-10-31
Phase Phase 4

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT02893293

The ClinicalTrials.gov registry entry for NCT02893293 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,921-participant average among 7 other Osteonecrosis trials with a reported enrollment target (100% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteonecrosis appearing as the primary indexed condition, and to 2 interventions - of which Ferumoxytol-enhanced magnetic resonance imaging is the first listed.

NCT02893293 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02893293 about?

NCT02893293 is a clinical study titled "Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI". The goal of the project is to evaluate osteonecrosis before and after decompression surgery with ferumoxytol-enhanced MRI.

What is the current status of trial NCT02893293?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2015-05. Estimated completion is 2023-10-31.

What conditions does trial NCT02893293 study?

This clinical trial studies the following conditions: Osteonecrosis.

What interventions are being tested in trial NCT02893293?

The interventions under investigation include: Ferumoxytol-enhanced magnetic resonance imaging (DRUG), Magentic Resonance Imaging (DEVICE).

Who is sponsoring clinical trial NCT02893293?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02893293 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteonecrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.